Pancreatic Cancer Research

ResearcherZhejiang Provincial People's HospitalNo recent work listed

Ming‐Hai Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4402-5018; OpenAlex author ID A5101742376. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper

Papers 7

  1. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy. Last author DOI 10.1016/j.bbcan.2020.188360↗
  2. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pa… Co-author DOI 10.3389/fonc.2019.01377↗
  3. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. Last author DOI 10.1021/acs.molpharmaceut.8b00298↗
  4. Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. Last author PMID 27293990↗
  5. Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Last author DOI 10.1158/1535-7163.mct-13-0242↗
  6. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. Co-author DOI 10.1371/journal.pone.0044883↗
  7. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutic… Last author DOI 10.1021/mp200193u↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hangping Yao · 6 shared papers, 2011–2020 · strength 0.51
  2. Chenyu W Hu · 2 shared papers, 2018–2019 · strength 0.17
  3. Ruiwen Zhang · 3 shared papers, 2011–2016 · strength 0.14
  4. Xiangming Xu · 1 shared paper, 2019 · strength 0.09
  5. Bo Hong · 1 shared paper, 2019 · strength 0.09
  6. Yun Qian · 1 shared paper, 2019 · strength 0.09
  7. Linghui Chen · 1 shared paper, 2018 · strength 0.08
  8. Weilin Wang · 1 shared paper, 2018 · strength 0.08
  9. Jun-Ying Zeng · 1 shared paper, 2014 · strength 0.05
  10. Snehal Padhye · 1 shared paper, 2011 · strength 0.03
  11. Hongxia Xu · 1 shared paper, 2012 · strength 0.03
  12. Wei Wang · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.